IDXX - Idexx Laboratories, Inc.
(NaN%)
SNP 500NASDAQ
Hold
Strong Growth and Improving
71%
based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 8.72%
Operating Income Growth is 22.07%
Net Income Growth is 24.44%
Earnings Per Share (EPS) Growth is 25.28%
Net Margin is 23.08%
Balance Sheet is MODERATE
Current Asset to Current Liability Ratio is 1.57
Debt Ratio is 0.54
Current Debt to Net Income Ratio is 0.09
Total Debt to Total Assets Ratio is 0.24
Cash Flow is STRONG
Cash from Operations Growth is 66.95%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Idexx Laboratories, Inc. (IDXX) - www.idexx.com
IDEXX Laboratories, Inc. is a member of the S&P 500® Index and is a leader in pet healthcare innovation, offering diagnostic and software products and services that deliver solutions and insights to practicing veterinarians around the world. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for livestock and poultry and tests for the quality and safety of water and milk and point-of-care and laboratory diagnostics for human medicine. Headquartered in Maine, IDEXX employs more than 9,000 people and offers products to customers in over 175 countries.Exchange - NASDAQ
Industry - In-Vitro Diagnostic Substance Manufacturing
Sector - Manufacturing
CEO - Jonathan Jay Mazelsky
Employees - 10,780
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.